Medtronic reported about 7% organic revenue growth in Q1 FY2027, boosted by new products like pulsed field ablation in its Cardiovascular and Spine divisions. Despite strong sales, margin expansion remains limited as management works to convert growth into sustainable earnings leverage. Risks include uncertainty after the MiniMed separation and potential slowing of new product growth. The upcoming December Investor Day is expected to provide more clarity on the company's long-term outlook.
Medtronic shares are trading at USD 95.52 on Pluang as of Oct 28, 2026 22:02 WIB, up 1.67% on the day with a market cap of $120.18 billion. The stock shows strong investor interest with 100% buy orders on the platform and a dividend yield of 3.07%. This trading activity complements the company's reported 7% organic revenue growth and upcoming Investor Day that may clarify its long-term prospects.
